Haemonetics (HAE) Share-based Compensation (2009 - 2026)

Haemonetics has reported Share-based Compensation for 18 years, with the latest figure at $9.3 million in Q2 2026.

• On a quarterly basis, Share-based Compensation changed 0.01% year-over-year to $9.3 million in Q2 2026; TTM through Jun 2026 was $33.8 million, a 15.85% increase from a year earlier, with the FY2026 full-year figure at $33.8 million, up 14.14% from the prior year.
• Share-based Compensation was $9.3 million for Q2 2026 at Haemonetics, up from $9.1 million in the prior quarter.
• The five-year high for Share-based Compensation was $9.8 million in Q2 2024, with the low at $4.7 million in Q3 2024.
• Average Share-based Compensation over 5 years is $7.3 million, with a median of $7.2 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation retreated 29.39% in 2024, then surged 60.27% in 2025.
• Over 5 years, Share-based Compensation stood at $7.5 million in 2022, then declined by 3.66% to $7.2 million in 2023, then grew by 13.81% to $8.2 million in 2024, then retreated by 5.05% to $7.8 million in 2025, then grew by 19.39% to $9.3 million in 2026.
• The last three Share-based Compensation figures came in at $9.3 million (Q2 2026), $9.1 million (Q1 2026), and $7.8 million (Q4 2025), per Business Quant data.